Literature DB >> 17569173

Minimizing tolerance and withdrawal to prolonged pediatric sedation: case report and review of the literature.

Hannah H Cho1, James P O'Connell, Maureen F Cooney, Mario A Inchiosa.   

Abstract

Midazolam and fentanyl infusions are commonly used for prolonged sedation and analgesia in the pediatric intensive care setting. Tolerance and withdrawal are major concerns when these infusions are used for days or weeks. Here, we review the current approaches to prolonged pediatric sedation using midazolam and fentanyl and discuss newer strategies to avoid tolerance and withdrawal syndromes. We report the case of a pediatric burn patient who developed tolerance syndrome and a movement disorder in our institution. We also review the relevant literature and methods of minimizing tolerance and withdrawal. Prolonged sedation is often necessary in treating critically ill children, and tolerance and abstinence syndrome can complicate a successful recovery. Scoring systems can be used to minimize oversedation and to titrate effectively. "Drug cycling," "wake-up protocols," and weaning regimens, possibly combined with adjuvant drugs, are being implemented successfully. Such novel approaches may decrease the incidence of tolerance and withdrawal associated with prolonged sedative and analgesic use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17569173     DOI: 10.1177/0885066607299556

Source DB:  PubMed          Journal:  J Intensive Care Med        ISSN: 0885-0666            Impact factor:   3.510


  9 in total

Review 1.  Risk factors associated with iatrogenic opioid and benzodiazepine withdrawal in critically ill pediatric patients: a systematic review and conceptual model.

Authors:  Kaitlin M Best; Joseph I Boullata; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2015-02       Impact factor: 3.624

2.  Use of methadone for opioid weaning in children: prescribing practices and trends.

Authors:  Kazim Giby; Régis Vaillancourt; Nisha Varughese; Christina Vadeboncoeur; Annie Pouliot
Journal:  Can J Hosp Pharm       Date:  2014-03

3.  Effects of Clonidine on Withdrawal From Long-term Dexmedetomidine in the Pediatric Patient.

Authors:  Allison B Lardieri; Nicholas M Fusco; Shari Simone; L Kyle Walker; Jill A Morgan; Kristine A Parbuoni
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jan-Feb

4.  Association Between Deep Sedation from Continuous Intravenous Sedatives and Extubation Failures in Mechanically Ventilated Patients in the Pediatric Intensive Care Unit.

Authors:  Jennifer M Schultheis; Travis S Heath; David A Turner
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Mar-Apr

5.  The Withdrawal Assessment Tool-1 (WAT-1): an assessment instrument for monitoring opioid and benzodiazepine withdrawal symptoms in pediatric patients.

Authors:  Linda S Franck; Sion Kim Harris; Deborah J Soetenga; June K Amling; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2008-11       Impact factor: 3.624

6.  Patterns of Sedation Weaning in Critically Ill Children Recovering From Acute Respiratory Failure.

Authors:  Kaitlin M Best; Lisa A Asaro; Linda S Franck; David Wypij; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2016-01       Impact factor: 3.624

7.  Assessment and treatment of the withdrawal syndrome in paediatric intensive care units: Systematic review.

Authors:  Jennihe Alejandra Ávila-Alzate; Juan Gómez-Salgado; Macarena Romero-Martín; Santiago Martínez-Isasi; Yolanda Navarro-Abal; Daniel Fernández-García
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 8.  The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial.

Authors:  Carrol Gamble; Andrew Wolf; Ian Sinha; Catherine Spowart; Paula Williamson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

Review 9.  Considerations for pediatric burn sedation and analgesia.

Authors:  Alice Fagin; Tina L Palmieri
Journal:  Burns Trauma       Date:  2017-10-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.